Although blockade of the checkpoint molecules LAG-3, PD1/PD-L1, and TIGIT aims to activate anti-tumor CD8+ cytotoxic T cells, they also reactivate and expand exhausted Tregs, contributing to therapy resistance [31,55,66,95,96]. Here, CD8A is linked to neoplasm.